Allscripts Healthcare Solutions Misses, Earnings Continue to Dip - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 8:50AM CDT
On a reported basis, Allscripts Healthcare Solutions (MDRX) incurred a broader loss of $20.7 million or 12 cents per share compared with $11.6 million or 7 cents in the first quarter of 2013
athenahealth Crumbles on Einhorn's Short Call - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 3:20PM CDT
Shares of athenahealth (ATHN) sunk nearly 15% to date after Einhorn's description of it as a "bubble stock."
Alere Q1 Earnings Rise, Revs Miss Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 12:10PM CDT
Since the earnings release, shares of Alere Inc. (ALR) rose 2.0% till yesterday.
Hanger Q1 Earnings and Revs Miss Ests, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 1:10PM CDT
For 2014, Hanger Inc. (HGR) lowered its adjusted earnings per share guidance to a range of $2.01 to $2.11 from the prior range of $2.10 to $2.20.
CareFusion's Flat Earnings Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 9:48AM CDT
CareFusion (CFN) upgraded its revenues and earnings guidance for fiscal 2014.
Wright Medical Group Sees Broader Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 11:30AM CDT
For 2014, Wright Medical Group, Inc. (WMGI) anticipates adjusted loss per share in the range of $1.28 to $1.38.
What Makes Vascular Solutions (VASC) a Strong Sell? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 7:54AM CDT
Vascular Solutions (VASC) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter as well as the current year.
Cardiovascular Systems (CSII) Jumps: Stock Rises 8.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 7:30AM CDT
Cardiovascular Systems (CSII) was a big mover last session, as its shares rose over 8% on the day.
LeMaitre Vascular (LMAT) in Focus: Stock Rises 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 01, 8:46AM CDT
LeMaitre Vascular was a big mover last session, with shares rising over 7% on the day.
Haemonetics Slips on Q4 Earnings and Revs Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 1:50PM CDT
Haemonetics Corporation (HAE) reports disappointing fourth-quarter and fiscal 2014 financial results.
Global Omega-3 Polyunsaturated Fatty Acids (PUFAs) Market Overview 2014-2020
M2 - Wed Apr 30, 8:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k99bvz/omega3) has announced the addition of the "Global Omega-3 Polyunsaturated Fatty Acids (PUFAs) Market Overview 2014-2020" report to their offering. Omega-3 Polyunsaturated Fatty Acid (PUFAs) ingredients market analyzed in this study include EPA and DHA omega-3s from marine oils such as fish oils, krill oils and squid oils; and algal oils. The end use application markets covered in the report include dietary supplements, food & beverages, pet nutrition, infant nutrition, pharmaceuticals and clinical nutrition. Worldwide, consumption of Omega-3 polyunsaturated fatty acids (PUFAs), estimated at 123.8 thousand metric tons worth US$2.3 billion in 2013, is forecast to be 134.7 thousand metric tons valued at US$2.5 billion in 2014. By 2020, it is projected that demand for Omega-3 PUFAs globally would reach 241 thousand metric tons with a value of US$4.96 billion, thereby posting a volume CAGR of almost 10% and a value CAGR of 11.6% between 2013 and 2020. This 410 page global market report includes 126 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of market numbers. The statistical tables represent the data for the global omega-3 ingredients market volume in metric tons and value in US$ by geographic region, the product segment and application area. This study profiles 42 key global players and 106 major players across North America - 29; Europe - 35; Asia-Pacific - 30 and Rest of World - 12. The report also provides the listing of the companies engaged in the manufacturing and supply of omega-3 PUFAs as well as major players in the omega-3 end-use industries such as human nutrition, pet nutrition and pharmaceuticals and major ingredient distributors across the globe. The global list of companies covers addresses, contact numbers and the website addresses of 294 companies. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. GLOBAL REGULATORY LANDSCAPE FOR OMEGA-3 FATTY ACIDS 3. KEY MARKET TRENDS 4. INDUSTRY STRUCTURE AND COMPETETIVE LANDSCAPE 5. KEY GLOBAL PLAYERS 6. KEY BUSINESS TRENDS 7. KEY PRODUCT/TECHNOLOGY TRENDS 8. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: OMEGA-3 PATENT LANDSCAPE PART
Abaxis' Fiscal Q4 Earnings, Revs Disappoint Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 10:50AM CDT
Abaxis, Inc. (ABAX) delivers disappointing fourth-quarter and fiscal 2014 financial results
AmSurg Lags Q1 Earnings & Revs, Trims 2014 EPS View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 8:40AM CDT
AmSurg Corp. (AMSG) delivers disappointing first-quarter 2014 financial results.
Align Technology Beats on Top & Bottom, Guides High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 8:11AM CDT
Align Technology Inc. (ALGN) delivers better-than-expected first-quarter 2014 results.
Enzymotec Ltd. Announces Signing of Final Settlement and License Agreement With Neptune
GlobeNewswire - Mon Apr 28, 7:46AM CDT
Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company"
Enzymotec Ltd. to Report First Quarter Fiscal Year 2014 Financial Results
GlobeNewswire - Mon Apr 28, 7:01AM CDT
Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today announced that it will release financial results for the first quarter ended March 31, 2014 on Wednesday, May 14, 2014, before the market opens. Following the release, the Company will host a conference call to discuss these results with additional comments and details. Participating on the call will be Dr. Ariel Katz, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer.
Neptune and Enzymotec Conclude Final Patent Infringement Settlement ad License Agreement
GlobeNewswire - Sun Apr 27, 7:33PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune"
Covidien Earnings Beat by a Penny - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 12:26PM CDT
Covidien (COV) reiterated its outlook for fiscal 2014.
Edwards Lifesciences Q1 Earnings Top, Revs Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 8:57AM CDT
Edwards Lifesciences (EW) delivers mixed first-quarter 2014 results.
Zimmer Holdings (ZMH) Soars: Stock Up 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 7:51AM CDT
Zimmer Holdings, Inc. (ZMH) was a big mover last session, as its shares rose nearly 12% on the day.